Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Advances in Noninvasive Prenatal Testing For Down Syndrome and other Trisomies. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Advances in Noninvasive Prenatal Testing For Down Syndrome and other Trisomies (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 106 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Noninvasive Prenatal Testing (NIPT) using Cell-free Fetal DNA (cfDNA)

A highly specific and sensitive NIPT method has recently become available as an alternative for prenatal screening tests that are currently in use. The NIPT method measures the level of circulating cell-free fetal DNA (cfDNA) present in maternal plasma to identify fetal aneuploidies, including Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). Fetal DNA represents approximately three to six percent of the total DNA in the maternal circulation. cfDNA typically can be detected in maternal plasma as early as the fifth postmenstrual week and almost always detected by the ninth postmenstrual week. Normally the percentage of fetal DNA increases with increasing gestational age.
One of the major challenges with identifying cfDNA is separating fetal DNA from maternal DNA . At present, there are two major techniques for isolating fetal DNA from maternal DNA: Massively parallel signature sequencing (MPSS) and directed DNA analysis.